Interleukin 31 (IL31) (N-Term) antibody

Details for Product No. ABIN1002634, Supplier: Log in to see
Antigen
  • IL31
  • IL-31
  • 1700013B14Rik
  • interleukin 31
  • IL31
  • Il31
Epitope
N-Term
18
15
10
7
5
5
4
3
3
1
1
1
1
1
1
1
Reactivity
Mouse (Murine)
89
31
8
Host
Rabbit
96
11
1
Clonality
Polyclonal
Conjugate
Un-conjugated
12
5
4
3
3
3
1
1
1
1
1
1
1
1
1
1
1
Application
Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
78
60
27
17
16
15
5
4
2
2
2
2
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen IL-31 antibody was raised against a 16 amino acid peptide from near the amino terminus of mouse IL-31 (Genbank accession No. AAS82846).
Blocking Peptide Blocking peptide for this product available: ABIN2861694
Isotype IgG
Purification Affinity chromatography purified via peptide column.
Alternative Name Interleukin 31 (IL31 Antibody Abstract)
Background Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.
Application Notes IL-31 antibody can be used for the detection of IL-31 by Western blot at 2.5 – 5 µg/ml. (Optimal dilution should be determined by user.) Antibody can also be used for immunohistochemistry and ELISA and might be suited for other applications not tested so far.
Restrictions For Research Use only
Format Liquid
Buffer Antibody is supplied in PBS containing 0.02% sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice Antibody can be stored at 4 °C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 myl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap.
Storage 4 °C
Expiry Date 12 months
Background publications Bilsborough, Leung, Maurer, Howell, Boguniewicz, Boguniewcz, Yao, Storey, LeCiel, Harder, Gross: "IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis." in: The Journal of allergy and clinical immunology, Vol. 117, Issue 2, pp. 418-25, 2006 (PubMed).

Diveu, Lak-Hal, Froger, Ravon, Grimaud, Barbier, Hermann, Gascan, Chevalier: "Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling." in: European cytokine network, Vol. 15, Issue 4, pp. 291-302, 2005 (PubMed).

Dreuw, Radtke, Pflanz, Lippok, Heinrich, Hermanns: "Characterization of the signaling capacities of the novel gp130-like cytokine receptor." in: The Journal of biological chemistry, Vol. 279, Issue 34, pp. 36112-20, 2004 (PubMed).

Dillon, Sprecher, Hammond, Bilsborough, Rosenfeld-Franklin, Presnell, Haugen, Maurer, Harder, Johnston, Bort, Mudri, Kuijper, Bukowski, Shea, Dong, Dasovich, Grant, Lockwood, Levin, LeCiel, Waggie et al.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. ..." in: Nature immunology, Vol. 5, Issue 7, pp. 752-60, 2004 (PubMed).